Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients

Fertility and Sterility

Volumn 81, Issue 3, 2004, Pages 562-566

  Escudero, Ernesto ^a   Bosch, Ernesto ^a   Crespo, Juana ^a   Simón, Carlos ^a,b   Remohí, José ^a,b   Pellicer, Antonio ^a,b,c  

^a INSTITUTO VALENCIANO DE INFERTILIDAD   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

GnRH antagonists; IVF embryo transfer outcome; Ovarian stimulation

Indexed keywords

ESTRADIOL; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY CYCLE; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; DRUG ADMINISTRATION SCHEDULE; EMBRYO IMPLANTATION; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS;

EID: 1642385240     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.07.027     Document Type: Article

References (18)

1. Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists a change for the better? Fertil Steril. 76:2001;443-444.
2. Al-Inany H., Aboulghar M. GnRH antagonist in assisted reproduction a Cochrane review. Hum Reprod. 17:2002;874-885.
3. Albano C., Felberbaum R.E., Smitz J., Riethmuller-Winzen H., Diedrich K., Devroey P., et al. Ovarian stimulation with HMG results of a prospective randomised phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 15:2000;526-531.
4. European Orgalutran Study Group. Treatment with the gonadotropin- releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient results of a controlled, randomised, multicentre trial. Hum Reprod. 15:2000;1490-1498.
5. European-Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 16:2001;644-651.
6. Olivennes F., Fanchin R., Bouchard P., Taieb J., Selva J., Frydman R. Scheduled administration of GnRH antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles a pilot study. Hum Reprod. 10:1995;1382-1386.
7. Diedrich K., Diedrich C., Santos E., Zoll C., Al-Hasani S., Reissmann T., et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 9:1994;788-791.
8. Felberbaum R., Diedrich K. Ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection with gonadotropins and gonadotrophin-releasing hormone analogues agonist and antagonist. Hum Reprod. 14:1999;207-221.
9. Olivennes F., Fanchin R., Bouchard P., de Ziegler D., Taieb J., Selva J., et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization-embryo transfer program. Fertil Steril. 62:1994;468-476.
10. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Siebert-Weigel M., Diedrich K., et al. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum Reprod. 11:1996;2114-2118.
11. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Van Steirteghem A., Devroey P. Comparison of different doses of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 67:1997;917-922.
12. Westergard L.G., Laursen S.B., Andersen C.Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Rep. 15:2000;1003-1008.
13. Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Rep 1998;13:1788-92
14. Ludwig M., Katalinic A., Banz C., Schroder A.K., Loning M., Weiss J.M., et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF results of a prospective, randomized study. Hum Reprod. 17:2002;2842-2845.
15. Pellicer A., Simón C., Miró F., Castellvi R.M., Ruiz A., Ruiz M., et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 4:1989;285-289.
16. Gil-Salom M., Mínguez Y., Rubio C., De los Santos M.J., Remohi J., Pellicer A. Efficacy of intracytoplasmic sperm injection using testicular spermatozoa. Hum Reprod. 10:1995;3166-3170.
17. Nikolettos N., Al-Hasani S., Felberbaum R., Demirel L.C., Kupker W., Montzka P., et al. Gonadotropin-releasing hormone antagonist protocol a novel method for ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol. 97:2001;202-207.
18. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders results of a prospective randomized trial. Hum Reprod. 16:2001;868-870.